Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences BioEngineering Summit 2019

Murat Cirit's Biography

Murat Cirit, Director at Translational Center of Tissue Chip Technologies, Massachusetts Institute of Technology (MIT)

Murat Cirit, PhD, is a Research Scientist at MIT & director of the Translational Systems Pharmacology Team. Murat completed his PhD at NCSU focusing on systems biology of growth factor-mediated signal transduction pathways. After completion of his PhD, he worked in the pharmaceutical industry focusing on preclinical drug discovery for oncology. He brings an interdisciplinary and systematic approach through his extensive experimental knowledge and computational modeling with an understanding of biological, physiological, and physical processes. His main research experience is systems pharmacology, systems biology, applied tissue engineering, cell biology and signal transduction networks. His current focus as the scientific lead is integrating various scientific fields to build interacting MPSs by interfacing platform engineering & tissue engineering for pharmacology studies.

Murat Cirit Image

Maximizing the Impact of Microphysiological Systems with In vitro–In vivo Translation

Monday, 1 April 2019 at 11:00

Add to Calendar ▼2019-04-01 11:00:002019-04-01 12:00:00Europe/LondonMaximizing the Impact of Microphysiological Systems with In vitro–In vivo

A large percentage of drug candidates fail at the clinical trial stage due to a lack of efficacy and unacceptable toxicity, primarily because the in vitro cell culture models and in vivo animal models commonly used in preclinical studies provide limited information about how a drug will affect human physiology. The need for more physiologically relevant in vitro systems for preclinical efficacy and toxicity testing has led to a major effort to develop “Microphysiological Systems (MPS)”, aka tissue chips (TC), based on engineered human tissue constructs.
Microphysiological systems  hold promise for improving therapeutic drug approval rates by providing more physiological, human-based, in vitro assays for preclinical drug development activities compared to traditional in vitro and animal models. The full impact of MPS technologies will be realized only when robust approaches for in vitro–in vivo (MPS-to-human) translation are developed and utilized, and explain how the burgeoning field of quantitative systems pharmacology (QSP) can fill that need.

Add to Calendar ▼2019-04-01 00:00:002019-04-02 00:00:00Europe/LondonBioEngineering Summit